News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Incyte Corporation Posts Wider Q3 Loss on Research Costs
November 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Nov 6 (Reuters) - Biotechnology company Incyte Corp posted a wider third-quarter loss, hurt by research and development costs that rose about 50 percent.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Incyte
MORE ON THIS TOPIC
Mergers & acquisitions
Concentra Snags Another Struggling Biotech as Cargo Accepts $200M Buyout
July 8, 2025
·
1 min read
·
Annalee Armstrong
Layoff Tracker
CSL Trims Research and Development Unit
July 8, 2025
·
152 min read
·
BioSpace Editorial Staff
Artificial intelligence
Roche’s Chugai Breaks Into Aging via Potential $1B+ Deal With AI Outfit Gero
July 7, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
July 3, 2025
·
3 min read
·
Annalee Armstrong
